Focusing on Three Canada Stocks Whose Volume Surged On Bullish Signals: $VXL $TEST $WAVE

The Market Signal was created as a platform to help investors, if you own (TSX:VXL), (TSX:TEST) or (TSX:WAVE) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/Free-Report/NOW
(Click link above or copy, paste and hit enter in your browser for your report)

Vaxil Bio focuses on the vivo (animal) study

https://themarketsignal.com/Free-Report/VXL

(Click link above or copy, paste and hit enter in your browser for your report)

Vaxil Bio Ltd. (TSX:VXL) is pleased after a volume of its 11.10 million shares gained by a margin of 50.00%.

Here are some latest updates from this innovative immunotherapy biotech company:

A company specializing in cancer and infectious diseases, VAXIL BIO LTD disclosed that it had started the vivo (animal) study for Vaxil's COVID-19 vaccine candidate (Corvax(TM)).The progressive study is being overseen by Tel Aviv Medical Centre's Director of the Allergy and Clinical Immunology called Dr.Hagin.The company saw a great need to undertake an evaluation of the immune response to Vaxil'sCorvax(TM), and soon its tool to injecting the fisrt animal. That was on July 14, 2020.

The administration of the Corvax(TM) injections over the past few weeks and have been completed already. The company's next move will be to evaluate the results, in which case it will be incorporating some of the findings obtained over the next four to six weeks. At some point, it says it will make a pronouncement of the results and the next steps forward.

FluroTech focuses on the FluroTest LLC ("FluroTest")

https://themarketsignal.com/Free-Report/TEST

(Click link above or copy, paste and hit enter in your browser for your report)

The 240.00% gain on a volume of 5.03 Million shares speaks well about the business performance of FluroTech Ltd. (TSX:TEST).

This company through a press release gave an update in line with its FluroTest LLC ("FluroTest"). To achieve its set objectives, the company struck alliances with companies such as Albany Medical College ("AMC") and Alberta BioPhotonics Inc. ("ABP") .The Company is pleased about its findings on the saliva-based immunoassay. According to it, product will play a huge role helping detect the various active SARS-CoV-2 infections considering that it is functioning quite well.

The FluroTest virus direct detection method checks out the salivary samples to determine the SARS-CoV-2 viral load, something made possible by fluorescence spectroscopy. It was at the Albany Medical College's immunology laboratories that the researchers undertook the prototype testing.

Waverley Pharma to commercialize six additional generic oncology products

https://themarketsignal.com/Free-Report/WAVE

(Click link above or copy, paste and hit enter in your browser for your report)

A volume of 2.71million shares belonging to Waverley Pharma Inc. (TSX:WAVE) gained by a figure of about 20.69%. The signing of a term sheet between the company's subsidiary called Waverley Pharma International Inc and Reliance Life Sciences Private Limited ("RLS") is commendable according to analysts. It gives the company the green light to focus in the commercialization of about six additional generic oncology products. RLS will ensure the finished products are supplied to the various customers, whereas Waverley Pharma will focus on getting the United States Food and Drug Administration to approve the products.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_370980379/2705/2020-09-09T06:33:22

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.